Pregnancy Demands Tighter Glucose Goals
Hyperglycemia-related pregnancy complications occur in 50% of pregnant women with type 1 diabetes.1
The American Diabetes Association2 and Lancet international consensus3 offer guidance for management of diabetes during pregnancy, including nutrition, exercise, and lifestyle management strategies.
Proven to Improve Time in Pregnancy Range (TIRp)
Just a 5% increase in TIRp is associated with a reduction in newborn complications.4
Read the full results of the CIRCUIT Randomized Controlled Trial
One System: Before, During and After Pregnancy
Tighter control means safer outcomes for mom and baby.
Simple Steps to Achieve Higher TIRp with Control-IQ+
Control-IQ+ does not need a “pregnancy-specific target” setting because it uses basal rates, carb ratios, Correction Factor, and Sleep Activity to achieve higher TIRp and lower mean glucose.
Step 1: Use Sleep Activity 24 hours per day
Sleep Activity sets a tighter treatment range of 112.5-120 mg/dL to help lower mean glucose
In the pump settings, set a Sleep Schedule from 12:00 AM to 11:59 PM and select all 7 days
Step 2: Make settings adjustments based on glycemia
Reassess settings every two weeks or sooner if there are patterns of hyperglycemia or hypoglycemia. Refer to the Average daily dose in the Insulin summary tile of the Tandem Source platform to calculate settings.
Other Important Pump Education Considerations
Educate on pre-bolusing considerations.
If you have additional questions or need clarification, please reach out to Tandem Medical Affairs at medicalaffairs@tandemdiabetes.com.
References
1. Donovan LE, et al. Closed-Loop Insulin Delivery in Type 1 Diabetes in Pregnancy: The CIRCUIT Randomized Clinical Trial. JAMA. 2025;334(24): 2176-2185.
2. American Diabetes Association Professional Practice Committee for Diabetes. 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S321-S338. 2.
3. Benhalima K, et al. Lancet Diabetes Endocrinol. 2026;14(2):157-177.
4. Sanusi AA, Xue Y, McIlwraith C, Howard H, Brocato BE, Casey B, Szychowski JM, Battarbee AN. Association of Continuous Glucose Monitoring Metrics With Pregnancy Outcomes in Patients With Preexisting Diabetes. Diabetes Care. 2024;47(1):89-96.
5. Donovan LE, Lemieux P, Yamamoto JM, et al. Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial. Diabetes Care. 2026;49(8):1339–1347.
Important Safety Information
RX ONLY. Tandem insulin pumps are intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. Tandem insulin pumps with Control-IQ+ technology are intended for the management of type 1 diabetes in individuals 2 years of age and greater and of type 2 diabetes in persons 18 years of age and greater. Control-IQ+ technology is intended for use in pregnancy complicated by type 1 diabetes mellitus, provided the linked CGM system is suitable for use in pregnancy. Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.